Beneficio del Tegoprazan en comparación con el Esomeprazol para el manejo de gastritis por elicobacter pylori: revisión sistemática

Abstract

Importance: A systematic review assessing the benefits of Tegoprazan compared to Esomeprazole for treating gastritis caused by Helicobacter pylori. Objective: To compare the efficacy, tolerability, and side effects of Tegoprazan versus Esomeprazole in the management of Helicobacter pylori-related gastritis. Methodology: Studies in humans over 18 years of age, published between 2020 and 2025, in English or Spanish, open-access, and with observational design or clinical trials were included. Reviews, case reports, and gray literature were excluded. Searches were conducted in PubMed, Scopus, Cochrane, and Taylor & Francis. The risk of bias was evaluated using the RoB2 tool for clinical trials and the JBI tool for observational studies. Results: Data were organized around efficacy, adherence, and adverse events. Eight studies (4 observational and 4 clinical trials) were included, with a total of more than 2000 patients. Tegoprazan showed comparable or better efficacy (91.1%), a lower incidence of adverse effects (28.0% versus 39.4%), and high adherence to treatment (>90%). Limitations included heterogeneity in treatment protocols, limited data on non-Asian populations, and moderate methodological risk in some studies. Conclusion: Tegoprazan is an effective and well-tolerated alternative to Esomeprazole, providing a viable treatment option, especially in cases of antibiotic resistance